Theravance CFO shares withheld for RSU taxes

Theravance Biopharma, Inc. reported that SVP & Chief Financial Officer Aziz Sawaf had 8,670 Ordinary Shares withheld at a price of $16.55 per share to cover tax obligations from vesting restricted stock units.

Accepted by SEC EDGAR 05/22/2026 - 06:25 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Theravance Biopharma, Inc. reported that SVP & Chief Financial Officer Aziz Sawaf had 8,670 Ordinary Shares withheld at a price of $16.55 per share to cover tax obligations from vesting restricted stock units. This was a share withholding with the company, not an open market trade. After this routine tax-withholding transaction, Sawaf directly holds 344,953 Ordinary Shares.

Insider Trade Summary

Exercise Price or Tax Liability: 8,670 shares

Exercise Price or Tax Liability 1 txn

Insider Sawaf Aziz

Role SVP & CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	8,670	$16.55	$143K

Holdings After Transaction: Ordinary Shares — 344,953 shares (Direct)

Holdings Before and After: Ordinary Shares, 353,623 to 344,953 shares (Direct)

Footnotes (1)

1. F1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

Key Figures

Shares withheld for taxes: 8,670 shares Withholding price per share: $16.55/share Shares held after transaction: 344,953 shares

3 metrics

Shares withheld for taxes 8,670 shares Tax-withholding disposition on Ordinary Shares

Withholding price per share $16.55/share Price used for tax-withholding transaction

Shares held after transaction 344,953 shares CFO’s direct Ordinary Share holdings post-transaction

Key Terms

restricted stock units, tax obligations, open market transaction, Ordinary Shares

4 terms

restricted stock units financial

"tax obligations arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligations financial

"Shares withheld to satisfy tax obligations arising out of the vesting"

open market transaction financial

"did not involve an open market transaction"

An open market transaction is a buy or sell of publicly traded securities executed on an exchange or other public trading venue where many buyers and sellers can participate. It matters to investors because these trades change the visible supply and demand for a stock—like shoppers moving prices in a busy marketplace—affecting share price, liquidity (how easily you can trade), and sometimes the balance of ownership.

Ordinary Shares financial

"security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Theravance Biopharma (TBPH) disclose about CFO Aziz Sawaf’s recent share transaction?

Theravance Biopharma disclosed that CFO Aziz Sawaf had 8,670 Ordinary Shares withheld at $16.55 per share. The shares were retained by the company to satisfy tax obligations from vesting restricted stock units, rather than being sold in the open market.

Was the Theravance Biopharma (TBPH) CFO’s Form 4 transaction an open market sale?

No, the transaction was not an open market sale. Shares were withheld by Theravance Biopharma to satisfy tax obligations tied to vesting restricted stock units, as noted in the footnote, and the withholding occurred in a transaction with the issuer itself.

How many Theravance Biopharma (TBPH) shares were withheld for the CFO’s taxes?

A total of 8,670 Ordinary Shares of Theravance Biopharma were withheld. The withholding price was $16.55 per share and was used to cover tax obligations arising from the vesting of previously granted restricted stock units held by the CFO.

How many Theravance Biopharma (TBPH) shares does CFO Aziz Sawaf hold after the Form 4 event?

Following the tax-withholding transaction, CFO Aziz Sawaf directly holds 344,953 Ordinary Shares of Theravance Biopharma. This figure reflects his position after 8,670 shares were withheld by the issuer to satisfy tax obligations from vesting restricted stock units.

What is the nature of the Form 4 transaction reported for Theravance Biopharma (TBPH) CFO?

The Form 4 transaction is coded “F,” indicating a tax-withholding disposition. Shares were delivered to the issuer to pay tax liabilities from restricted stock unit vesting, rather than being voluntarily sold or purchased in the open market by the executive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sawaf Aziz

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/20/2026		F		8,670(1)	D	$16.55	344,953	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)